Related references
Note: Only part of the references are listed.PROTAC-DB: an online database of PROTACs
Gaoqi Weng et al.
NUCLEIC ACIDS RESEARCH (2021)
Drug Syntheses Beyond the Rule of 5
Mohit Tyagi et al.
CHEMISTRY-A EUROPEAN JOURNAL (2020)
Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay
Caroline A. Foley et al.
ACS CHEMICAL BIOLOGY (2020)
Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space
Giulia Caron et al.
DRUG DISCOVERY TODAY (2020)
Assays and technologies for developing proteolysis targeting chimera degraders
Xingui Liu et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Emerging New Concepts of Degrader Technologies
Yu Ding et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
Andy Pike et al.
DRUG DISCOVERY TODAY (2020)
Degraders early developability assessment: face-to-face with molecular properties
Giuseppe Ermondi et al.
DRUG DISCOVERY TODAY (2020)
Understanding and Improving the Membrane Permeability of VH032-Based PROTACs
Victoria G. Klein et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges
Scott D. Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Permeability prediction for zwitterions via chromatographic indexes and classification into 'certain' and 'uncertain'
Francesco Caudana et al.
FUTURE MEDICINAL CHEMISTRY (2019)
A MedChem toolbox for cereblon-directed PROTACs
Christian Steinebach et al.
MEDCHEMCOMM (2019)
Developing degraders: principles and perspectives on design and chemical space
Hannah J. Maple et al.
MEDCHEMCOMM (2019)
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
CRISPR-Cas guides the future of genetic engineering
Gavin J. Knott et al.
SCIENCE (2018)
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem et al.
CELL CHEMICAL BIOLOGY (2018)
Targeted protein degradation by PROTACs
Taavi K. Neklesa et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
Updating molecular properties during early drug discovery
Giulia Caron et al.
DRUG DISCOVERY TODAY (2017)
Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs
Adrian Whitty et al.
DRUG DISCOVERY TODAY (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Bradley Croy Doak et al.
CHEMISTRY & BIOLOGY (2014)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
